Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | S100A4 | P26447 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8796187 | 0.87 | CYP1A2 (0.47) | CYP1A2TSHRALDH1A1KAT2BHSD17B10 | |
| SCHEMBL4578481 | 0.84 | TSHR (0.47) | CYP1A2TSHRALDH1A1KAT2BCTSD | |
| SCHEMBL16809212 | 0.84 | ALDH1A1 (0.49) | CYP1A2TSHRALDH1A1HSD17B10CTSD | |
| Hydrochloric Acid SCHEMBL5816350 | 0.82 | KAT2B (0.50) | CYP1A2TSHRALDH1A1KAT2BHSD17B10 | |
| SCHEMBL7153686 | 0.81 | CYP1A2 (0.53) | CYP1A2TSHRALDH1A1KAT2BHSD17B10 | |
| SCHEMBL12232402 | 0.81 | CYP1A2 (0.53) | CYP1A2TSHRALDH1A1KAT2BHSD17B10 | |
| SCHEMBL16805954 | 0.81 | ALDH1A1 (0.46) | CYP1A2TSHRALDH1A1HSD17B10CTSD | |
| SCHEMBL15245035 | 0.81 | ALDH1A1 (0.46) | CYP1A2TSHRALDH1A1HSD17B10CTSD | |
| SCHEMBL9098602 | 0.80 | KAT2B (0.47) | CYP1A2TSHRALDH1A1KAT2BHSD17B10 | |
| SCHEMBL7775829 | 0.80 | CYP1A2 (0.58) | CYP1A2TSHRALDH1A1HSD17B10CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021105916-A1 | SULFONAMIDE COMPOUNDS TARGETING CD73 AND ADENOSINE RECEPTORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-06-03 | — | — | WO | disclosed |
| US-7915420-B2 | Aryl piperidine amides | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-20080009521-A1 | Aryl Piperidine Amides | HUANG CHARLES Q | 2008-01-10 | — | — | US | disclosed |
| US-7276610-B2 | Aryl piperidine amides | JANSSEN PHARACEUTICA, NV (BE) | 2007-10-02 | — | — | US | disclosed |
| EP-1660472-A1 | ARYL PIPERIDINE AMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005021525-A1 | ARYL PIPERIDINE AMIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-10 | — | — | WO | disclosed |
| US-20050049239-A1 | Aryl piperidine amides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-03 | — | — | US | disclosed |
| WO-2003026666-A1 | 2-PHENYLAMINO-4- (5-PYRAZOLYLAMINO)-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS, IN PARTICULAR, AS SRC KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009521-A1 | Aryl Piperidine Amides | BDNF, NTRK2, OPRL1 | CYP1A2 2066/4885TSHR 1678/4885ALDH1A1 952/4885 |
| US-20050049239-A1 | Aryl piperidine amides | BDNF, NTRK2, OPRL1 | CYP1A2 2066/4885TSHR 1678/4885ALDH1A1 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.